Lannett Co (LCI) – Research Analysts’ Recent Ratings Updates

Several analysts have recently updated their ratings and price targets for Lannett Co (NYSE: LCI):

  • 11/14/2017 – Lannett Co was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Lannett, Inc. manufactures and distributes pharmaceutical products sold under generic names and historically has manufactured and distributed pharmaceutical products sold under its trade or brand names. In addition, the Company contract manufactures and private labels pharmaceutical products for other companies. “
  • 11/13/2017 – Lannett Co had its price target raised by analysts at BMO Capital Markets from $20.00 to $22.00. They now have a “market perform” rating on the stock.
  • 11/10/2017 – Lannett Co was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $28.00 price target on the stock. According to Zacks, “Lannett, Inc. manufactures and distributes pharmaceutical products sold under generic names and historically has manufactured and distributed pharmaceutical products sold under its trade or brand names. In addition, the Company contract manufactures and private labels pharmaceutical products for other companies. “
  • 11/9/2017 – Lannett Co was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 10/24/2017 – Lannett Co was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Lannett, Inc. manufactures and distributes pharmaceutical products sold under generic names and historically has manufactured and distributed pharmaceutical products sold under its trade or brand names. In addition, the Company contract manufactures and private labels pharmaceutical products for other companies. “
  • 10/2/2017 – Lannett Co was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.

Lannett Co Inc (LCI) traded up $1.95 on Friday, hitting $27.50. The stock had a trading volume of 754,324 shares, compared to its average volume of 790,798. Lannett Co Inc has a 1-year low of $14.90 and a 1-year high of $27.90. The stock has a market capitalization of $962.40, a price-to-earnings ratio of 9.50, a P/E/G ratio of 2.13 and a beta of 2.73. The company has a debt-to-equity ratio of 1.44, a quick ratio of 1.90 and a current ratio of 2.52.

Lannett Co (NYSE:LCI) last released its quarterly earnings results on Monday, November 6th. The company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.52 by $0.08. Lannett Co had a return on equity of 18.23% and a net margin of 6.67%. The business had revenue of $155.00 million during the quarter, compared to analyst estimates of $153.62 million. During the same period last year, the business posted $0.77 earnings per share. The company’s quarterly revenue was down 4.1% on a year-over-year basis. research analysts expect that Lannett Co Inc will post 2.99 earnings per share for the current year.

In other news, CEO Arthur P. Bedrosian sold 7,422 shares of the firm’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $25.20, for a total transaction of $187,034.40. Following the completion of the transaction, the chief executive officer now directly owns 679,001 shares in the company, valued at $17,110,825.20. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder David Farber sold 10,000 shares of Lannett Co stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $25.03, for a total value of $250,300.00. Following the completion of the transaction, the insider now owns 4,211,069 shares of the company’s stock, valued at $105,403,057.07. The disclosure for this sale can be found here. Company insiders own 15.04% of the company’s stock.

Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.

Receive News & Ratings for Lannett Co Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett Co Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.